{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:08:57Z","timestamp":1792696137700,"version":"4.5.0"},"reference-count":184,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104874, 81904200"],"award-info":[{"award-number":["82104874, 81904200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Alopecia areata (AA) is a prevalent autoimmune condition characterized by hair loss, with the collapse of hair follicle immune privilege being a pivotal event in its pathogenesis. This collapse involves intricate immunological disturbances, where CD8\n                    <jats:sup>+<\/jats:sup>\n                    NKG2D\n                    <jats:sup>+<\/jats:sup>\n                    T cells, driven by inflammatory cytokines like IFN-\u03b3, attack hair follicles. Additionally, various immune cell, including Th1, Th2, Th17 cells, \u03b3\u03b4T cells, NK cells, and mast cells, contribute to this pathological process. Defects in the function of Tregs, Bregs, and iNKT cells further compound the immune imbalance. At the molecular level, the JAK-STAT pathway emerges as a central regulatory node integrating multiple cytokine signals and presenting itself as a significant therapeutic target. JAK inhibitors have shown notable effectiveness in clinical settings, with some agents even gaining FDA approval for treating moderate-to-severe AA. However, the effectiveness of targeting IL-17, TNF-\u03b1, Th2 cytokines, PDE4, and other molecules remains debated. This review comprehensively explores the dynamic interactions among immune cell subsets, cytokine networks, and crucial signaling pathways in AA pathogenesis. It also summarizes the latest clinical progress and challenges in targeted therapies. Future studies should delve deeper into AA\u2019s immune regulatory framework and devise tailored treatment approaches to enhance patient outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1621492","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T04:14:03Z","timestamp":1756700043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology"],"prefix":"10.3389","volume":"16","author":[{"given":"Huai-Bo","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Mi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/pde.15803","article-title":"Epidemiology of pediatric alopecia areata","author":"Adhanom","year":"2025","journal-title":"Pediatr Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00805-4","article-title":"Comorbid conditions associated with alopecia areata: A systematic review and meta-analysis","volume":"24","author":"Ly","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70076","article-title":"Global burden of alopecia areata and associated diseases: A trend analysis from 1990 to 2021","volume":"24","author":"Zhou","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2461483","article-title":"Efficacy, safety and tolerability of drugs for alopecia: A comprehensive review","volume":"21","author":"Valdez-Zertuche","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ddg.14689","article-title":"Alopecia areata - current understanding and management","volume":"20","author":"Lintzeri","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/biomedicines11082153","article-title":"Exploring the pathogenesis and mechanism-targeted treatments of rosacea: Previous understanding and updates","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.059","article-title":"Microneedle transdermal delivery of compound betamethasone in alopecia areata-a randomized controlled trial","volume":"92","author":"Qiao","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.8499","article-title":"Comparative efficacy of intralesional steroid injections vs cryotherapy for the treatment of alopecia areata","volume":"24","author":"Akram","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae085","article-title":"Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: A single-centre retrospective analysis","volume":"49","author":"Lee","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7431","article-title":"Review of superficial cryotherapy for the treatment of alopecia areata","volume":"22","author":"Kaiser","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13010","article-title":"Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin","volume":"32","author":"Ibrahim","year":"2019","journal-title":"Dermatol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14447","article-title":"Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: Experience from a tertiary healthcare institution in Singapore","volume":"33","author":"Leong","year":"2020","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23876","article-title":"Fractional co(2) laser and minoxidil in the treatment of alopecia areata, a comparative study","volume":"57","author":"Elhawary","year":"2025","journal-title":"Lasers Surg Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15630","article-title":"Effect of fractional laser alone or in combination on alopecia areata: A systematic review and meta-analysis","volume":"22","author":"Shen","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2016.1248440","article-title":"A review on laser and light-based therapies for alopecia areata","volume":"19","author":"Mlacker","year":"2017","journal-title":"J Cosmet Laser Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13613","article-title":"Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years","volume":"44","author":"Jun","year":"2017","journal-title":"J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14084","article-title":"Combination of photodynamic therapy with 5-aminolaevulinic acid and microneedling in the treatment of alopecia areata resistant to conventional therapies: Our experience with 41 patients","volume":"45","author":"Giorgio","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115403","article-title":"Ala-pdt augments intense inflammation in the treatment of acne vulgaris by cox2\/trem1 mediated m1 macrophage polarization","volume":"208","author":"Liu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2024.104238","article-title":"A novel h\u2212tert immortalized human sebaceous gland cell line (xl-i-20) for the investigation of photodynamic therapy","volume":"48","author":"Liu","year":"2024","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.01.018","article-title":"The 5-aminolevulinic acid photodynamic therapy modulates lipid production by protein kinase b\/jund-mediated nr4a1 activation in the treatment of acne vulgaris","author":"Wu","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1203475421995712","article-title":"Oral methotrexate monotherapy for severe alopecia areata: A single center retrospective case series","volume":"25","author":"Kinoshita-Ise","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1886230","article-title":"Efficacy and predictive factors of cyclosporine a in alopecia areata: A systematic review with meta-analysis","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13206","article-title":"Methotrexate in the treatment of paediatric alopecia areata: Retrospective case series and updated meta-analysis","volume":"61","author":"Phan","year":"2020","journal-title":"Australas J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16858","article-title":"Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: A retrospective study of continuation rates in 138 patients","volume":"34","author":"Lai","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxz039","article-title":"Pathomechanisms of immune-mediated alopecia","volume":"31","author":"Anzai","year":"2019","journal-title":"Int Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01151-5","article-title":"Deciphering the molecular mechanisms of stem cell dynamics in hair follicle regeneration","volume":"56","author":"Lee","year":"2024","journal-title":"Exp Mol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.3390\/ijms25115652","article-title":"Deciphering the complex immunopathogenesis of alopecia areata","volume":"25","author":"\u0160uti\u0107 Udovi\u0107","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdev.2022.203793","article-title":"Immune-mediated alopecias and their mechanobiological aspects","volume":"170","author":"Watson","year":"2022","journal-title":"Cells Dev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103061","article-title":"The current state of knowledge of the immune ecosystem in alopecia areata","volume":"21","author":"Connell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/itt.S266409","article-title":"Alopecia areata: An autoimmune disease of multiple players","volume":"10","author":"Suchonwanit","year":"2021","journal-title":"Immunotargets Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2005.11.003","article-title":"Cd200, a \u201cno danger\u201d signal for hair follicles","volume":"41","author":"Rosenblum","year":"2006","journal-title":"J Dermatol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2061396","article-title":"Pd-l1 blockade potentiates the antitumor effects of ala-pdt and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma","volume":"11","author":"Zeng","year":"2022","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: An update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00807.x","article-title":"The hair follicle and immune privilege","volume":"8","author":"Paus","year":"2003","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.035","article-title":"Frontiers in alopecia areata pathobiology research","volume":"144","author":"Gilhar","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405215","article-title":"Type-2 immunity associated with type-1 related skin inflammatory diseases: Friend or foe","volume":"15","author":"Migayron","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","article-title":"Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese dermatological association guidelines","volume":"49","author":"Fukuyama","year":"2022","journal-title":"J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of t-cell activity in alopecia areata: Recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-020-00673-w","article-title":"Alopecia areata: A review on diagnosis, immunological etiopathogenesis and treatment options","volume":"21","author":"Sterkens","year":"2021","journal-title":"Clin Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.004","article-title":"Identification of autoantigen epitopes in alopecia areata","volume":"136","author":"Wang","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14070","article-title":"Immune cell regulation of the hair cycle","volume":"29","author":"Wang","year":"2020","journal-title":"Exp Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13718","article-title":"Interferon-gamma serum level and immunohistochemical expression of cd8 cells in tissue biopsies in patients with alopecia areata in correlation with trichoscopic findings","volume":"33","author":"Agamia","year":"2020","journal-title":"Dermatol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.03.008","article-title":"Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies","volume":"15","author":"Gilhar","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305764120","article-title":"Functional interrogation of lymphocyte subsets in alopecia areata using single-cell rna sequencing","volume":"120","author":"Lee","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.14815","article-title":"Advances in the mechanism and new therapies of alopecia areata","volume":"26","author":"Jin","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: A multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J Autoimmun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.17","article-title":"Increased expression of cxcr3 and its ligands, cxcl9 and cxcl10, during the development of alopecia areata in the mouse","volume":"132","author":"McPhee","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01547-5","article-title":"A virtual memory cd8(+) t cell-originated subset causes alopecia areata through innate-like cytotoxicity","volume":"24","author":"Seok","year":"2023","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.056","article-title":"Increased blood levels of nkg2d(+)cd4(+) t cells in patients with alopecia areata","volume":"76","author":"Jang","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23692.x","article-title":"Transfer of cd8(+) cells induces localized hair loss whereas cd4(+)\/cd25(-) cells promote systemic alopecia areata and cd4(+)\/cd25(+) cells blockade disease onset in the c3h\/hej mouse model","volume":"124","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating th2\/tc2\/th22, within the skin-homing and systemic t-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.2.156","article-title":"The contributory roles of th17 lymphocyte and cytotoxic t lymphocyte at the hair bulge region as well as the hair bulb area in the chronic alopecia areata patients","volume":"29","author":"Hong","year":"2017","journal-title":"Ann Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jaci.2019.08.014","article-title":"Il-12\/il-23 neutralization is ineffective for alopecia areata in mice and humans","volume":"144","author":"Ortolan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12978","article-title":"Imbalance of t-helper 17 and regulatory t cells in patients with alopecia areata","volume":"42","author":"Han","year":"2015","journal-title":"J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1823-y","article-title":"Il-17 inhibition: Is it the long-awaited savior for alopecia areata","volume":"310","author":"Ramot","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00403-024-02901-9","article-title":"Elucidating the role of t-reg related cytokines: Serum transforming growth factor beta and interleukin-35 in alopecia areata","volume":"316","author":"Yuksek","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114259","article-title":"Changes and significance of th1\/th2 and treg\/th17 cells and their cytokines in patients with alopecia areata","volume":"442","author":"Yang","year":"2024","journal-title":"Exp Cell Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12791","article-title":"Regulatory t cells in skin","volume":"152","author":"Ali","year":"2017","journal-title":"Immunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.874778","article-title":"Selective expansion of tregs using the il-2 cytokine antibody complex does not reverse established alopecia areata in c3h\/hej mice","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S297858","article-title":"Application of topical immunotherapy in the treatment of alopecia areata: A review and update","volume":"15","author":"Mahasaksiri","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111547","article-title":"The potential of regulatory t cell-based therapies for alopecia areata","volume":"14","author":"Wan","year":"2023","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210308","article-title":"Alopecia areata patients show deficiency of foxp3+cd39+ t regulatory cells and clonotypic restriction of treg tcr\u03b2-chain, which highlights the immunopathological aspect of the disease","volume":"14","author":"Hamed","year":"2019","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102711","article-title":"Resident human dermal \u03b3\u03b4t-cells operate as stress-sentinels: Lessons from the hair follicle","volume":"124","author":"Uchida","year":"2021","journal-title":"J Autoimmun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.09.001","article-title":"Pro-inflammatory v\u03b41(+)t-cells infiltrates are present in and around the hair bulbs of non-lesional and lesional alopecia areata hair follicles","volume":"100","author":"Uchida","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaut.2018.04.001","article-title":"Inkt cells ameliorate human autoimmunity: Lessons from alopecia areata","volume":"91","author":"Ghraieb","year":"2018","journal-title":"J Autoimmun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01934-9","article-title":"Macrophage migration inhibitory factor polymorphism (rs755622) in alopecia areata: A possible role in disease prevention","volume":"311","author":"Rajabi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: A review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1159\/000247111","article-title":"Changes in populations of hla-dr+cd3+ cells and cd57-cd16+ cells in alopecia areata after corticosteroid therapy","volume":"188","author":"Imai","year":"1994","journal-title":"Dermatology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2010.01106.x","article-title":"An unexpected twist in alopecia areata pathogenesis: Are nk cells protective and cd49b+ t cells pathogenic","volume":"19","author":"Kaufman","year":"2010","journal-title":"Exp Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1539-1","article-title":"Lesional infiltration of mast cells, langerhans cells, t cells and local cytokine profiles in alopecia areata","volume":"307","author":"Zhang","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.07.009","article-title":"Plasmacytoid dendritic cells as a possible key player to initiate alopecia areata in the c3h\/hej mouse","volume":"69","author":"Ito","year":"2020","journal-title":"Allergol Int"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12932","article-title":"Plasmacytoid dendritic cells in alopecia areata: Missing link","volume":"30","author":"Abou Rahal","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1684\/ejd.2010.0816","article-title":"Plasmacytoid dendritic cells and dermatological disorders: Focus on their role in autoimmunity and cancer","volume":"20","author":"Charles","year":"2010","journal-title":"Eur J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and cd8+ t-cells may contribute to the pathogenesis of alopecia areata","volume":"9","author":"Bertolini","year":"2014","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/dad.0000000000001929","article-title":"Lesson to learn from cellular infiltrate in scalp biopsy of alopecia areata","volume":"43","author":"Genedy","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80768","article-title":"Involvement of ilc1-like innate lymphocytes in human autoimmunity, lessons from alopecia areata","volume":"12","author":"Laufer Britva","year":"2023","journal-title":"Elife"},{"key":"B79","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jid.2022.11.006","article-title":"Il-10\u2013producing potency from blood b cells correlates with the prognosis of alopecia areata","volume":"143","author":"Matsumura","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501798","article-title":"Cxcr3 blockade inhibits t cell migration into the skin and prevents development of alopecia areata","volume":"197","author":"Dai","year":"2016","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic t lymphocytes and is reversed by jak inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.S172638","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5109772","article-title":"Interleukin-15 and tumor necrosis factor-\u03b1 in Iraqi patients with alopecia areata","volume":"2023","author":"Kamil","year":"2023","journal-title":"Dermatol Res Pract"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15658","article-title":"Ifn-\u03b1 and tnf-\u03b1 serum levels and their association with disease severity in Egyptian children and adults with alopecia areata","volume":"60","author":"Omar","year":"2021","journal-title":"Int J Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s13770-021-00392-7","article-title":"Restoration of immune privilege in human dermal papillae controlling epithelial-mesenchymal interactions in hair formation","volume":"19","author":"Park","year":"2022","journal-title":"Tissue Eng Regener Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23888.x","article-title":"Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in c3h\/hej mice","volume":"125","author":"Freyschmidt-Paul","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2020.08.015","article-title":"Low-dose il-2 for treating moderate to severe alopecia areata: A 52-week multicenter prospective placebo-controlled study assessing its impact on t regulatory cell and nk cell populations","volume":"141","author":"Le Duff","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"Freyschmidt-Paul","year":"2006","journal-title":"Br J Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103217","article-title":"Interleukin-15 is a hair follicle immune privilege guardian","volume":"145","author":"Suzuki","year":"2024","journal-title":"J Autoimmun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd1866","article-title":"Blockade of il-7 signaling suppresses inflammatory responses and reverses alopecia areata in c3h\/hej mice","volume":"7","author":"Dai","year":"2021","journal-title":"Sci Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14293","article-title":"Ccl13 is upregulated in alopecia areata lesions and is correlated with disease severity","volume":"30","author":"Wang","year":"2021","journal-title":"Exp Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia areata: Current treatments and new directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows th1, th2, and il-23 cytokine activation without parallel th17\/th22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/all.16268","article-title":"Alopecia areata exhibits cutaneous and systemic ox40 activation across atopic backgrounds","volume":"79","author":"Kim","year":"2024","journal-title":"Allergy"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12273","article-title":"Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata","volume":"40","author":"Inui","year":"2013","journal-title":"J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/ijms23031038","article-title":"Lifestyle factors involved in the pathogenesis of alopecia areata","volume":"23","author":"Minokawa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14775","article-title":"Role of t helper 17 cells and t regulatory cells in alopecia areata: Comparison of lesion and serum cytokine between controls and patients","volume":"32","author":"Loh","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","article-title":"The il-23\/il-17 pathway in inflammatory skin diseases: From bench to bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum th1, th2, and th17 cytokines in patients with alopecia areata: Clinical implications","volume":"10","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"Cells"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2010.1041","article-title":"Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy","volume":"4","author":"S\u0142owi\u0144ska","year":"2010","journal-title":"J Dermatol Case Rep"},{"key":"B103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D34G31C0TM","article-title":"Letter: Alopecia areata during ustekinumab administration: Co-existence or an adverse reaction","volume":"18","author":"Verros","year":"2012","journal-title":"Dermatol Online J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14118","article-title":"Elevated serum tumour necrosis factor-like weak inducer of apoptosis in alopecia areata: A possible marker of disease severity","volume":"45","author":"Sayed","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00403-024-03788-2","article-title":"Exploring the effect of hsa-mir-19b-3p on il-1r1 expression and serum levels in alopecia areata","volume":"317","author":"AbdElneam","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444777","article-title":"Humanized cxcl12 antibody delays onset and modulates immune response in alopecia areata mice: Insights from single-cell rna sequencing","volume":"15","author":"An","year":"2024","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"799","DOI":"10.25259\/ijdvl_1093_2022","article-title":"Janus kinase inhibitors for alopecia areata: A narrative review","volume":"89","author":"Haughton","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2021.03.005","article-title":"Alopecia areata: New treatment options including janus kinase inhibitors","volume":"39","author":"Zheng","year":"2021","journal-title":"Dermatol Clin"},{"key":"B109","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jisp.2017.10.014","article-title":"Hair follicle immune privilege revisited: The key to alopecia areata management","volume":"19","author":"Paus","year":"2018","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B110","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jisp.2020.04.004","article-title":"Current treatment of alopecia areata","volume":"20","author":"Hordinsky","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.14712\/23362936.2023.1","article-title":"Janus kinase inhibitors in the treatment of alopecia areata","volume":"124","author":"Stefanis","year":"2023","journal-title":"Prague Med Rep"},{"key":"B112","doi-asserted-by":"publisher","first-page":"adv42990","DOI":"10.2340\/actadv.v105.42990","article-title":"Real-world effectiveness and safety of janus kinase inhibitors in alopecia areata: A retrospective cohort study of 72 patients","volume":"105","author":"Van Helmond","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41420-022-00927-4","article-title":"Regulation of the tec family of non-receptor tyrosine kinases in cardiovascular disease","volume":"8","author":"Yin","year":"2022","journal-title":"Cell Death Discov"},{"key":"B114","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00403-024-03229-0","article-title":"A review of tec family kinases and their inhibitors in the treatment of alopecia areata","volume":"316","author":"An","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jid.2022.09.656","article-title":"Aire deficiency leads to the development of alopecia areata\u2013like lesions in mice","volume":"143","author":"Maglakelidze","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: What\u2019s new in the epidemiology, comorbidities, and pathogenesis","volume":"112","author":"Dainichi","year":"2023","journal-title":"J Dermatol Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14432","article-title":"Nlrp3 inflammasome activation contributes to development of alopecia areata in c3h\/hej mice","volume":"31","author":"Hashimoto","year":"2022","journal-title":"Exp Dermatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14844","article-title":"The crosstalk between pten-induced kinase 1-mediated mitophagy and the inflammasome in the pathogenesis of alopecia areata","volume":"33","author":"Shin","year":"2024","journal-title":"Exp Dermatol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/ijms26041565","article-title":"The involvement of ripk1 in alopecia areata","volume":"26","author":"Kim","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1111\/exd.70074","article-title":"Ikzf1 and ikaros overexpression results in alopecia areata-like phenotype in mice","volume":"34","author":"Arakawa","year":"2025","journal-title":"Exp Dermatol"},{"key":"B121","article-title":"Association analysis of the ikzf4 gene with alopecia areata in the chinese han population","volume":"30","author":"Miao","year":"2024","journal-title":"Altern Ther Health Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jdermsci.2023.05.005","article-title":"Sirt1 downregulation provokes immune-inflammatory responses in hair follicle outer root sheath cells and may contribute to development of alopecia areata","volume":"111","author":"Hao","year":"2023","journal-title":"J Dermatol Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3934\/mbe.2021037","article-title":"Genome-wide expression profiling of long non-coding rnas and competing endogenous rna networks in alopecia areata","volume":"18","author":"Qi","year":"2020","journal-title":"Math Biosci Eng"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2019.1597109","article-title":"The association between genetic variation in wnt transcription factor tcf7l2 (tcf4) and alopecia areata","volume":"48","author":"Rajabi","year":"2019","journal-title":"Immunol Invest"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12171","article-title":"Assessment of tissue levels of dickkopf-1 in androgenetic alopecia and alopecia areata","volume":"15","author":"Fawzi","year":"2016","journal-title":"J Cosmet Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of fda-approved small molecule protein kinase inhibitors: A 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2444494","article-title":"Baricitinib for the treatment of severe alopecia areata: Results from a 52-week multicenter retrospective real-world study","volume":"36","author":"Vignoli","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from brave-aa1 and brave-aa2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16666","article-title":"Comparative efficacy and safety of baricitinib against traditional therapies in severe alopecia areata: A retrospective cohort study","volume":"24","author":"Stefanis","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae033","article-title":"Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib","volume":"49","author":"Tang","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of ctp-543, a selective janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective janus kinase inhibitor, in adults with alopecia areata: Results from the phase 3 randomized, controlled trial (thrive-aa1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188","article-title":"Pf-06651600, a dual jak3\/tec family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral jak3\/tec family kinase inhibitor, for the treatment of alopecia areata from the allegro clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17539","article-title":"Efficacy and safety of ritlecitinib in asian patients with alopecia areata: A subgroup analysis of the allegro phase 2b\/3 trial","volume":"52","author":"Zhang","year":"2025","journal-title":"J Dermatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.064","article-title":"Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the allegro phase 2b\/3 trial","volume":"92","author":"Piliang","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the allegro phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16049","article-title":"Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran","volume":"23","author":"Asilian","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15917","article-title":"Alopecia areata and tofacitinib: A prospective multicenter study from a saudi population","volume":"61","author":"AlMarzoug","year":"2022","journal-title":"Int J Dermatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00403-024-03203-w","article-title":"Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: A double-blind, randomized controlled trial","volume":"316","author":"Paracha","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16356","article-title":"Safety and efficacy of tofacitinib in 97 alopecia areata patients","volume":"23","author":"Nasimi","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14325","article-title":"Real-world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients","volume":"65","author":"Cranwell","year":"2024","journal-title":"Australas J Dermatol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/ijdvl_1755_2024","article-title":"Efficacy and safety of tofacitinib in patients with total and universal alopecia- a retrospective evaluation of 69 patients","author":"Lin","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553904","article-title":"Significant efficacy of tofacitinib from China in the treatment of alopecia areata: A case report","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"adv13475","DOI":"10.2340\/actadv.v103.13475","article-title":"Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: A retrospective study","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"adv13418","DOI":"10.2340\/actadv.v103.13418","article-title":"Effectiveness of tofacitinib in pre-adolescent alopecia areata: A retrospective case series and literature review","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/1346-8138.17064","article-title":"Alopecia areata: What\u2019s new in the diagnosis and treatment with jak inhibitors","volume":"51","author":"Dainichi","year":"2024","journal-title":"J Dermatol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17909","article-title":"Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib","volume":"36","author":"Winnette","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf345","article-title":"Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib","author":"Yong","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1177\/2050313x231213135","article-title":"Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report","volume":"11","author":"Oliel","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase ii study to evaluate the efficacy and safety of ivarmacitinib (shr0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15504","article-title":"Improvement of severe alopecia areata in an adolescent patient on upadacitinib","volume":"41","author":"Ha","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"adv5578","DOI":"10.2340\/actadv.v103.5578","article-title":"Upadacitinib for successful treatment of alopecia universalis in a child: A case report and literature review","volume":"103","author":"Yu","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16342","article-title":"Assessment of alopecia areata universalis successfully treated with upadacitinib","volume":"62","author":"Gori","year":"2023","journal-title":"Int J Dermatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.056","article-title":"Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study","volume":"89","author":"Flora","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15896","article-title":"Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib","volume":"23","author":"Huang","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2242706","article-title":"Successful treatment of alopecia universalis with abrocitinib: A case report","volume":"34","author":"Zhang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac103","article-title":"Cross-specialty identification of the jak1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata","volume":"188","author":"Fagan","year":"2023","journal-title":"Br J Dermatol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02336-0","article-title":"A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata","volume":"315","author":"Mikhaylov","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70076","article-title":"A novel topical compound gel loading minoxidil and tofacitinib for treatment of alopecia areata: Formulation, characterization, and in vitro\/in vivo evaluation","volume":"86","author":"Wang","year":"2025","journal-title":"Drug Dev Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.010","article-title":"Cause or cure? Review of dupilumab and alopecia areata","volume":"88","author":"Marks","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15136","article-title":"Dupilumab for alopecia areata treatment: A double-edged sword","volume":"21","author":"Jin","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-il-4r\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1111\/all.15561","article-title":"Scalp biomarkers during dupilumab treatment support th2 pathway pathogenicity in alopecia areata","volume":"78","author":"Renert-Yuval","year":"2023","journal-title":"Allergy"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15691","article-title":"Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review","volume":"41","author":"Metko","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17010","article-title":"Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata","volume":"63","author":"Tavoletti","year":"2024","journal-title":"Int J Dermatol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13699","article-title":"Response to ustekinumab in three pediatric patients with alopecia areata","volume":"36","author":"Aleisa","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by il-12\/il-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14826","article-title":"Treatment of chronic alopecia areata with tildrakizumab: An open-label pilot study","volume":"59","author":"Kerkemeyer","year":"2020","journal-title":"Int J Dermatol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14527","article-title":"Development of alopecia in patients treated with interleukin-17 inhibitors","volume":"33","author":"Antoury","year":"2020","journal-title":"Dermatol Ther"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1853-5","article-title":"Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata","volume":"310","author":"Guttman-Yassky","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.5070\/d3271156085","article-title":"Off-label uses of tnf-a inhibitors and il-12\/23 inhibitors in dermatology","volume":"27","author":"Hong","year":"2021","journal-title":"Dermatol Online J"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.11.009","article-title":"The pde4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin","volume":"77","author":"Keren","year":"2015","journal-title":"vivo. J Dermatol Sci"},{"key":"B179","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00403-018-1876-y","article-title":"A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata","volume":"311","author":"Mikhaylov","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B180","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00403-024-03642-5","article-title":"Comparing the efficacy of oral apremilast, intralesional corticosteroids, and their combination in patients with patchy alopecia areata: A randomized clinical controlled trial","volume":"317","author":"Awasthi","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18810","article-title":"Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors","volume":"37","author":"Gupta","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1616046","article-title":"Apremilast is efficacious in refractory alopecia areata","volume":"31","author":"Taneja","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12934","article-title":"Improvement of alopecia areata with apremilast","volume":"60","author":"Magdaleno-Tapial","year":"2019","journal-title":"Australas J Dermatol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.264","article-title":"Alefacept for severe alopecia areata: A randomized, double-blind, placebo-controlled study","volume":"145","author":"Strober","year":"2009","journal-title":"Arch Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T04:14:06Z","timestamp":1756700046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1621492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":184,"alternative-id":["10.3389\/fimmu.2025.1621492"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1621492","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1621492"}}